Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Stopped This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.

Conditions

• Multiple Myeloma

Interventions

• DRUG: Magrolimab
• DRUG: Daratumumab
• DRUG: Pomalidomide
• DRUG: Dexamethasone
• DRUG: Bortezomib
• DRUG: Carfilzomib

Sponsor

Gilead Sciences